TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All adults 18 years and older.~* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visit and completion of the diary cards) should be enrolled in the study.~* Written informed consent obtained from the subject.~* If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions .~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period.~* Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.~* History of hypersensitivity to a previous dose of influenza vaccine.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg, chicken protein, gelatine, formaldehyde, gentamicin sulphate, thimerosal or sodium deoxycholate.~* Acute disease at the time of enrollment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature \<37.5°C (99.5°F) / Axillary temperature \<37.5°C (99.5°F)).~* History of Guillain Barré syndrome within 6 weeks of prior receipt of inactivated influenza virus vaccine.~* Pregnancy and lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Design and Clinical Evaluation of a School Meal With Deworming Properties

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting parents and guardians~Exclusion Criteria:~* children with known allergy to papaya fruit products

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Papaya seed porridge (Type: EXPERIMENTAL): Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
- Albendazole and Plain porridge (Type: ACTIVE_COMPARATOR): Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
- Plain porridge (Type: PLACEBO_COMPARATOR): arm receiving 300ml plain porridge daily (without papaya seeds)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients of age 18 years or above~* Patients diagnosed with stage 1 or stage 2 essential hypertension~* Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant~Exclusion Criteria:~* Secondary hypertension or severe hypertension~* Clinically significant cardiovascular disease or heart failure~* A medical contraindication to discontinuing a current antihypertensive therapy~* History of Type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Nebivolol and Valsartan free tablet combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of heartburn \>2 days per week off antireflux therapy, defined by a burning feeling rising from the stomach or lower chest up towards the neck~* Symptoms of gastroparesis \>1 month in duration, defined by nausea, vomiting, bloating, dyspepsia, early satiety, or effortless regurgitation.~* Prior abnormal 4-hour gastric emptying scan within the past 3 years~Exclusion Criteria:~* History of esophageal or gastric surgery~* Severe gastroparesis with any of the following: vomiting with dehydration requiring IV hydration, hospitalization, weight loss \>10 % pre-illness weight, requiring feeding jejunostomy tubes~* Presence of gastric electrical stimulator~* Symptoms of retching with vomiting more than 2 days per week~* Diagnosis of diabetes~* Disorders of small bowel motility (such as pseudo-obstruction or dumping syndrome)~* Disorders of small bowel absorption~* Diagnosis of gastric outlet, small bowel or colon mechanical obstruction~* Diagnosis of acid hypersecretory syndrome~* Disorders affecting proton pump inhibitor metabolism (such as liver failure)~* Known allergy or side effects to proton pump inhibitor~* Non-ambulatory patients: bed-ridden, nursing home resident, etc.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Immediate-release omeprazole release first (Type: EXPERIMENTAL): subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
- Delayed-release omeprazole first (Type: EXPERIMENTAL): subjects receive delayed release omeprazole for 7 days then immediate release for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Twelve (12) weeks or longer of two or more of the following signs and symptom consistent with chronic rhinosinusitis (CRS)~• mucopurulent drainage (anterior, posterior, or both), nasal obstruction (congestion),facial pain-pressure-fullness, and decreased sense of smell~AND inflammation documented by one or more of the following findings:~* purulent (not clear) mucus or edema in the middle meatus or ethmoid region,~* polyps in nasal cavity or the middle meatus, and/or~* radiographic imaging showing inflammation of the paranasal sinuses~Exclusion Criteria:~* Unable to speak English~* History of comorbid ciliary dyskinesia, cystic fibrosis or any other mucociliary condition~* Dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease.~* History of oral or systematic antibiotic use in the past 2 weeks~* History of nasal or sinus surgery within past 6 weeks~* History of cerebrospinal fluid leak~* History of allergy to budesonide or other topical steroids~* Pregnant or breast feeding~* Current infection or history of one of the following infections: Tuberculosis (TB) lung infection, or Herpes infection of the eye.~* Baseline SNOT-22 total scores below 9 were excluded due to the inability to achieve a minimally clinically improved difference

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80.
- Saline Alone (Type: PLACEBO_COMPARATOR): Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Latent TB Infection for Jailed Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by positive tuberculin skin test (a documented reactive tuberculin skin test to 0.1 mL containing 5 Tuberculin Units) who meet current national criteria for therapy for tuberculosis infection and can provide informed consent.~Exclusion Criteria:~* Ineligible for either therapy regimen for any of the following reasons:~  1. history of treatment-limiting reaction to isoniazid or rifamycins;~ 2. pregnancy or breast feeding;~ 3. active tuberculosis;~ 4. an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 times the upper limit of normal;~ 5. bilirubin \>2 times the upper limit of normal;~ 6. platelets \<150 K/mm3;~ 7. taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs);~* Unable to communicate in English or Spanish;~* Unable or unwilling to provide informed consent;~* Not in the routine level of jail security for any reason (housed in special security areas);~* Any condition that, in the best judgment of the investigator, would pose a risk to the subject during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): isoniazid (INH) (900 mg orally) given twice weekly for 9 months
- A (Type: ACTIVE_COMPARATOR): rifampin (600 mg orally) given daily for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Village Interactive Training and Learning Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60+~* Generally Healthy~* On stable does of medications~* Absence of significant behavioral or cognitive dysfunction~Exclusion Criteria:~* Significant cognitive or behavioral problems or symptoms~* History of falls \>2 in the past month~* Unstable medical conditions such as uncontrolled diabetes, uncontrolled cardiac disease, uncontrolled hypertension, or other that would increase risk of side effects performing physical activity~* History of substance abuse in last 6 months~* Known structural brain abnormality, previous major debilitating strokes or seizures, traumatic brain injury~* Had complete neuropsychological testing in the last 6 months~* Previous participation in cognitive or exercise training study within last 3 months~* Currently engaging in moderate to heavy exercise \>125 mins. week at 75% Target Heart Rate

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Cognitive Training plus Exercise (Type: EXPERIMENTAL): Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training.
- Cognitive Training plus Exergames (Type: ACTIVE_COMPARATOR): Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training.
- Cognitive Training (Type: ACTIVE_COMPARATOR): Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 or older~* Able to understand protocol and agree to 3 visits~* Any type of glaucoma~* Selective laser trabeculoplasty, Argon laser trabeculoplasty, peripheral iridotomy accepted~* Naïve: No prior glaucoma treatment (medical or surgical)~* If patient non-compliant, must be off meds 3 months~* Xalatan: At least one month use~Exclusion Criteria:~* Both Groups: Any history of ocular surface disease~* Dry eye syndrome or prior Restasis use~* Prior ocular surgery other than cataract extractions~* Uveitis or other inflammatory disease of the eye or adnexa~* Systemic medications that might influence ocular inflammation~* Any active inflammation or infection~* Pregnancy or intention to become pregnant~* Naïve: Prior use of topical glaucoma medication unless off for 3 months.~* Use of preserved artificial tear preparations in last 30 days and more than one year history of chronic use~* Xalatan: Prior use of Travatan or Travatan Z

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New to Meds (Type: OTHER): Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
- Currently on Xalatan (Type: OTHER): Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration Study of OPC-12759 Ophthalmic Suspension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Out patient;~2. Ocular discomfort severity is moderate to severe;~3. Corneal-conjunctival damage is moderate to severe;~4. Unanesthetized Schirmer's test score of 5mm/5minutes or less,or tear breakup time is 5 seconds or less;~5. Best corrected visual acuity of 0.2 or better in both eyes.~Exclusion Criteria:~1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca;~2. Ocular hypertention patient or glaucoma patient with ophthalmic solution;~3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;~4. Anticipated use of contact lens during the study;~5. Patient with punctal plug;~6. Any history of ocular surgery within 12 months;~7. Female patients who are pregnant, possibly pregnant or breast feeding;~8. Known hypersensitivity to any component of the study drug or procedual medications;~9. Receipt of any investigational product within 4 months.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OPC-12759 Ophthalmic suspension (Type: EXPERIMENTAL): Instillation, 4times/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.~* HER2+ status defined as IHC 3+ staining or in situ hybridization positive~* Patients with resistance to trastuzumab~* Prior taxane therapy~* Patients with an ECOG performance status of 0 - 2~* Patients with measurable disease as per RECIST criteria~* Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study;~* Patients must meet laboratory criteria defined in the study within 21 days prior to randomization~Exclusion Criteria:~* Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer~* More than three prior chemotherapy lines for advanced disease.~* Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed \>8 weeks prior to randomization~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus~* Peripheral neuropathy ≥ grade 2 at randomization~* Active cardiac disease~* History of cardiac dysfunction~* Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer~* Known hypersensitivity to any study medication~* Breastfeeding or pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + vinorelbine + trastuzumab (Type: EXPERIMENTAL): Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
- placebo + vinorelbine + trastuzumab (Type: PLACEBO_COMPARATOR): Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Buspirone in Opiate Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* fulfilled DSM IV diagnostic criteria for opioid dependence~* used heroin daily for at least the prior 6 months with claimed heroin use of at least 2.5g/week~* physical dependence on opiates as determined by history and observation~* admission urine samples demonstrating heroin use~* expressed willingness to participate in a randomized, double-blind, placebo-controlled study for 14 days.~Exclusion Criteria:~* current or past Axis I psychiatric disorder other than opioid dependence~* evidence of significant neurological, gastrointestinal, hepatic, cardiovascular, renal, endocrine or hematologic disease~* seropositive status for the human immunodeficiency virus

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete